<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003603</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066676</org_study_id>
    <secondary_id>RHG-MM97</secondary_id>
    <secondary_id>EU-98030</secondary_id>
    <nct_id>NCT00003603</nct_id>
  </id_info>
  <brief_title>Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma</brief_title>
  <official_title>A Randomised Study Comparing CIDEX (CCNU, Oral Idarubicin and Dexamethasone) With Melphalan and Prednisolone in Relapsed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Riverside Haematology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Combining more than one drug may kill more cancer cells.&#xD;
      Steroids, such as dexamethasone or prednisolone, may help relieve some of the side effects of&#xD;
      chemotherapy. It is not yet known which regimen of chemotherapy plus steroid therapy is more&#xD;
      effective in treating patients with multiple myeloma.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of&#xD;
      chemotherapy plus steroid therapy in treating patients with multiple myeloma that has&#xD;
      recurred for the first time.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the response rate, response duration, and survival of patients with relapsed&#xD;
           multiple myeloma after treatment with lomustine, idarubicin, and dexamethasone vs&#xD;
           melphalan and prednisolone.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are stratified according to prior autologous&#xD;
      transplant (yes vs no). Patients are randomized to one of two treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral lomustine on day 1, oral idarubicin once daily on days 1-3,&#xD;
           and oral dexamethasone twice a day on days 1-4. Treatment is repeated every 28 days for&#xD;
           6-9 courses in the absence of unacceptable toxicity or disease progression.&#xD;
&#xD;
        -  Arm II: Patients receive oral melphalan once daily on days 1-4 and oral prednisolone&#xD;
           twice a day on days 1-4. Treatment is repeated every 28 days for 6-9 courses in the&#xD;
           absence of unacceptable toxicity or disease progression.&#xD;
&#xD;
      Some patients may receive oral cyclophosphamide every 7 days and oral prednisolone on&#xD;
      alternate days for 6 weeks concurrently with chemotherapy in either treatment arm.&#xD;
&#xD;
      Quality of life is assessed at baseline, at 3, 6, 9, and 12 months, and then every 6 months&#xD;
      thereafter.&#xD;
&#xD;
      Patients are followed until death.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 660 patients will be accrued for this study within 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 1998</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">660</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>idarubicin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lomustine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisolone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of multiple myeloma based on at least two of the following:&#xD;
&#xD;
               -  Paraprotein in serum and/or urine&#xD;
&#xD;
               -  Greater than 10% plasma cells in bone marrow&#xD;
&#xD;
               -  Lytic bone lesions&#xD;
&#xD;
          -  Measurable serum and/or urine paraprotein&#xD;
&#xD;
          -  Progression from first or second stable plateau phase&#xD;
&#xD;
          -  No non-secretory myeloma or plasma cell leukemia (greater than 2,000/mm^3 circulating&#xD;
             plasma cells)&#xD;
&#xD;
          -  No primary refractory disease or second or later relapse&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  0-3&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Neutrophil count at least 1,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 75,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT/AST no greater than 2.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 3.4 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No clinically significant cardiac insufficiency&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No uncontrolled diabetes mellitus&#xD;
&#xD;
          -  No recent history of peptic ulceration&#xD;
&#xD;
          -  HIV-1 and HIV-2 negative&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 6 months after study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior allogeneic peripheral blood stem cell or bone marrow transplantation&#xD;
&#xD;
          -  No planned future autologous transplantation unless sufficient stored stem cells&#xD;
             available&#xD;
&#xD;
          -  Prior interferon allowed if administered as maintenance of stable plateau phase&#xD;
&#xD;
          -  No concurrent epoetin alfa&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 3 months since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Concurrent radiotherapy for pain or to treat localized tumors allowed&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior participation in any clinical trial with an unlicensed product&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana Samson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hammersmith Hospitals NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W12 ONN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2001</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 19, 2013</last_update_submitted>
  <last_update_submitted_qc>September 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2013</last_update_posted>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Lomustine</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

